Wegovy reviews in the UK: What patients really say about weight loss, side effects, and results

DoktorABC editorial team

Accurate, up-to-date health information written by our editorial team and reviewed by UK-registered prescribers.

Wegovy reviews UK: What is the overall sentiment?

The overall picture from UK patient reviews is broadly positive, with the majority of people who complete the full titration reporting meaningful weight loss and improved wellbeing. 

The most consistent themes in positive reviews are appetite suppression, reduced food preoccupation, and steady, sustainable weight loss. Conversely, the most common themes among the negative reviews are gastrointestinal side effects (particularly in the early titration phase), cost, and frustration with pen availability at certain dose levels.

The review landscape therefore tends to overrepresent both ends of the spectrum. Clinical trial data provides a more statistically reliable picture of typical outcomes.

Wegovy weight loss reviews: What patients say about results

Weight loss is the primary reason most people seek out Wegovy, and the reviews are largely positive, with most patients reporting meaningful progress when they stick with the treatment through the titration phase. 

Common themes in weight-loss reviews include:

• Noticeable appetite reduction within the first one to two weeks, even on the lowest starting dose of 0.25 mg.
• Steady, gradual weight loss that accelerates after the first dose increase to 0.5 mg and beyond.
• Many patients describe the experience as the first time they have felt genuinely in control of their eating.
• Results that feel more sustainable than previous diet attempts, because the appetite suppression removes the willpower battle.
• A subset of patients who report slower or more modest results, particularly those who did not make concurrent dietary changes.

The theme of lifestyle adherence runs strongly through positive reviews. Patients who combine Wegovy with dietary changes and increased physical activity consistently report stronger outcomes than those who rely on the medication alone. This aligns with the clinical trial design, where all STEP participants received monthly behavioural counselling alongside the medication.

Wegovy before and after: What people experience during treatment

Patient reviews become most useful when they are broken down by timepoint. The experience of someone in their first two weeks on Wegovy looks very different from someone at six months, and understanding what is typical at each stage helps set realistic expectations for your own journey. Let’s explore. 

The first two to four weeks

The earliest reviews tend to focus on two things: appetite suppression that arrives sooner than expected, and side effects that are more pronounced than anticipated.

Most patients describe the first month as a period of adjustment rather than dramatic transformation. Weight loss is beginning, but the primary change most people notice is in their relationship with food: smaller portions, reduced cravings, and less preoccupation with eating.

The second and third month

By months two and three, most patients have moved through the 0.5 mg and 1 mg doses. Reviews from this timeframe commonly describe visible changes in body composition, clothes fitting differently, and comments from people around them. This is also the phase where many people find their footing with side effects: the nausea that was most pronounced in the early weeks has typically settled, and the appetite suppression has become more consistent.

Six months and beyond

Reviews from patients at the six-month mark and beyond tend to be more reflective and balanced. Weight loss is continuing but at a slower pace than the early months. Many describe a shift in focus from the scales to broader health improvements: better blood pressure readings, improved mobility, reduced joint pain, and higher energy levels.

What patients praise most about Wegovy

Based on recurring themes across UK reviews and patient forums, the most consistently praised aspects of Wegovy are:

• Appetite suppression: Described by many as transformative; the reduction in constant hunger and food preoccupation is frequently cited as the most significant change
• Ease of use: The pre-filled pen is straightforward to use and once-weekly dosing is convenient; reviews consistently praise the simplicity of the injection process
• Steady, gradual weight loss: Unlike crash diets, weight loss on Wegovy tends to be gradual and sustained, which many patients find easier to manage psychologically
• Improved relationship with food: Many reviews describe a shift from eating out of habit, boredom, or anxiety to eating in response to genuine hunger
• Broader health improvements: Blood pressure, blood sugar, cholesterol, and joint health improvements are frequently mentioned alongside weight loss in longer-term reviews
• Reduced food noise: The quieting of constant food-related thoughts is one of the most frequently mentioned benefits, particularly among patients who had previously struggled with compulsive eating patterns

What patients criticise most about Wegovy

The negative themes in Wegovy reviews are also consistent and worth understanding clearly before starting treatment:

• Gastrointestinal side effects: Nausea, vomiting, diarrhoea, constipation, and burping are the most frequently cited complaints, particularly in the early weeks of each new dose. Most patients describe these as manageable; a minority find them severe enough to consider stopping.
• Cost: Private prescription costs are a significant and a recurring concern, with monthly costs at the 2.4 mg maintenance dose ranging from approximately £169 to £289 depending on the provider. Many reviews mention the financial burden of sustaining treatment long term.
• Pen availability: Supply issues have affected certain dose levels at various points since Wegovy launched in the UK, causing frustration among patients mid-titration.
• Weight regain on stopping: Reviews from patients who have stopped Wegovy frequently describe regaining weight relatively quickly, which aligns with clinical trial data showing that weight regain is the norm after discontinuation without sustained lifestyle changes.
• Inconsistent results: A minority of reviewers report modest weight loss despite completing the full titration, which is statistically expected given the range of individual responses seen in clinical trials.

Wegovy on Trustpilot, Reddit, and patient forums

Online communities and review platforms provide a different but complementary perspective to clinical data. The themes below reflect patterns that emerge consistently across platforms, described without attributing specific invented quotes.

Trustpilot

Reviews on Trustpilot for Wegovy and associated UK providers tend to focus more on the service experience (delivery, consultation process, clinical support) than on the medication itself. Where the medication is discussed, the themes mirror those already mentioned, namely, strong appetite suppression, manageable but real gastrointestinal side effects, and results that build gradually rather than arriving overnight.

Reddit (r/WeightLossAdvice, r/Semaglutide, r/GLP1)

Reddit communities tend to attract more detailed, candid accounts than formal review platforms. Common themes include detailed week-by-week progress tracking, troubleshooting of side effects, discussion of what to eat to minimise nausea, and frank conversations about the emotional and psychological aspects of weight loss. A recurring theme on Reddit is the sense of community among people on GLP-1 treatments, with users sharing tips on injection technique, dietary adjustments, and managing plateaus. Negative threads tend to focus on cost and the challenge of accessing NHS treatment.

Patient forums and health communities

On broader health forums and platforms such as Mumsnet and Patient.info, discussions about Wegovy often centre on NHS eligibility, the experience of accessing treatment privately, and the emotional impact of significant weight loss. Hair loss (telogen effluvium) is discussed frequently as an unexpected and distressing but temporary side effect. The question of how long to stay on Wegovy is a consistent topic, with many patients expressing uncertainty about whether treatment is lifelong.

Clinical evidence vs patient experience: How do they compare?

Understanding how clinical trial results translate into real-world experience helps set realistic expectations.

The STEP 1 trial, published in the New England Journal of Medicine in 2021, found that participants lost an average of 14.9% of their body weight over 68 weeks on Wegovy 2.4 mg. More than 86% lost at least 5% of their starting weight, around 69% lost at least 10%, and approximately one-third lost 20% or more. 

Real-world results tend to be somewhat lower than trial averages. Real-world data suggests average weight loss of 8 to 12%, compared to the 14.9% seen in STEP 1, with the difference primarily attributable to lower adherence and dose-holding outside a clinical trial setting.

The key modifying factors are the same in both settings: lifestyle adherence, consistency of dosing, and the level of clinical support available.

The STEP 5 trial, published in Nature Medicine in 2022, extended the follow-up to 104 weeks (two years) and showed that weight loss was maintained over the longer term in patients who continued treatment, providing reassurance for patients considering Wegovy as a long-term option.

For the new Wegovy 7.2 mg dose, approved by the MHRA in January 2026, the STEP UP trial found a mean weight loss of 21% over 72 weeks, with more than 90% of participants achieving at least 5% weight loss and one-third losing 25% or more. Patient experience data at this higher dose is still limited given its recent availability, but the tolerability profile was broadly consistent with the standard 2.4 mg dose in trial conditions. 

Who tends to get the best results from Wegovy?

Clinical trial data and real-world patterns point to several factors that predict stronger outcomes with Wegovy.

Based on STEP trial data and UK clinical experience, patients who tend to see the best results are those who:

• Combine Wegovy with meaningful dietary changes, particularly reducing ultra-processed food intake and prioritising protein, which supports muscle preservation and satiety.
• Engage in regular physical activity, ideally combining cardiovascular exercise with resistance training to preserve muscle mass during weight loss.
• Titrate consistently and complete the full schedule, reaching the 2.4 mg maintenance dose without prolonged dose-holding due to side effects.
• Have higher starting weights, as absolute weight loss in kg tends to be larger, though percentage loss is broadly comparable across body sizes.
• Have access to regular clinical support, whether through a private clinic with check-ins or NHS specialist services, as structured follow-up improves adherence and outcomes.
• Do not have type 2 diabetes, as weight loss in non-diabetic participants was slightly greater in the STEP trials, with STEP 1 (non-diabetic) showing 14.9% loss versus 9.6% in STEP 2 (with type 2 diabetes).

Conversely, patients who find it difficult to tolerate gastrointestinal side effects, those who cannot sustain dietary changes alongside treatment, and those who have to stop and restart due to supply issues or cost tend to see more modest real-world results.

Final thoughts

The picture that emerges from UK Wegovy reviews is consistent with what the clinical evidence predicts: meaningful weight loss for most people who complete the titration, driven primarily by appetite suppression and improved satiety, with a side effect profile that is manageable for the majority but challenging for a minority.

What the reviews also make clear is that Wegovy works best as part of a broader approach. The patients who report the strongest, most sustained outcomes are those who use the medication alongside genuine dietary change, regular activity, and consistent clinical support, not as a standalone solution. If you are considering Wegovy, the most important first step is a conversation with a UK-registered prescriber who can assess your individual suitability and support you through the process.

FAQ

The DoktorABC medical advisory board

Dr. Roland Ruiken

Medical advisor, Norway

Dr. Viktor Simunovic

Medical advisor, Croatia

To the medical advisory board